<i id='766A60A89A'><strike id='766A60A89A'><tt id='766A60A89A'><pre id='766A60A89A'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
At least 13 dead in Texas as scorching temps continue 
Biotech startup Celsius cuts 75% of staff ahead of first trial start 
Medical records are filled with copy 
A bus careens into a gulch in southern Mexico, leaving 27 people dead 
Psychedelics group wrestles with new pharma identity 
Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’ 
In age of alternative facts, a scholarly course on calling out crap 
FDA scientists endorse Pfizer/BioNTech Covid 
After affirmative action ruling, medical educators look to 'holistic review' 
Listen: Biotech layoffs, eye drug drama, & gene therapy milestones 
Jerome Adams on the need for new antivirals for Covid 
Alnylam reports growth in sales of rare disease treatments 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
When waiting feels immoral: Empathy in the emergency department 
Trump demands the U.S. pay no more for drugs than other countries … again 
